Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders

The company has secured approvals to commence Phase I trials of SRSD216, designed to treat hyperlipoproteinemia in individuals with atherosclerotic cardiovascular conditions. Credit: Ali Hajiluyi on Unsplash.